| Tag | Content |
|---|
EnhancerAtlas ID | HS082-01405 |
Organism | Homo sapiens |
Tissue/cell | HCASMC |
Coordinate | chr1:90358930-90360980 |
TF binding sites/motifs | | TF | JASPAR ID | Coordinate | Motif Sequence | Strand | -Log10(p-value) |
| BCL6 | MA0463.2 | chr1:90358947-90358963 | TTTTCCTAGAAAGCAT | - | 7.56 | | BCL6B | MA0731.1 | chr1:90358945-90358962 | TTTTTTCCTAGAAAGCA | - | 6.69 | | MNX1 | MA0707.1 | chr1:90359391-90359401 | TTTAATTACC | - | 6.02 | | Mecom | MA0029.1 | chr1:90360767-90360781 | AAGAAAAGATAAGC | + | 6 | | PHOX2A | MA0713.1 | chr1:90359388-90359399 | TAATTTAATTA | + | 6.62 | | PROP1 | MA0715.1 | chr1:90359388-90359399 | TAATTTAATTA | - | 6.32 | | PROP1 | MA0715.1 | chr1:90359388-90359399 | TAATTTAATTA | + | 6.62 | | Phox2b | MA0681.1 | chr1:90359388-90359399 | TAATTTAATTA | + | 6.62 | | STAT1 | MA0137.3 | chr1:90358948-90358959 | TTTCCTAGAAA | - | 6.14 |
|
| | Number of super-enhancer constituents: 8 | ID | Coordinate | Tissue/cell |
| SE_13550 | chr1:90358983-90359617 | CD34_Primary_RO01536 | | SE_13550 | chr1:90360024-90364011 | CD34_Primary_RO01536 | | SE_14642 | chr1:90358807-90375291 | CD4_Memory_Primary_7pool | | SE_20971 | chr1:90359113-90374716 | CD8_Memory_7pool | | SE_37826 | chr1:90358848-90360757 | HSMMtube | | SE_38798 | chr1:90358783-90361076 | HUVEC | | SE_40012 | chr1:90359400-90360783 | K562 | | SE_46203 | chr1:90358805-90360913 | Osteoblasts |
|
| | Diseases: AD,Huntington,Obesity,Parkinson,Prostate cancer,Schizophrenia and Sleep disorder | | Number of disease enhancers: 1 | Chromosome | Start | End |
|
| | Number: 1 | ID | Chromosome | Start | End |
| GH01I089893 | chr1 | 90359258 | 90363903 |
|
Enhancer Sequence | AATATTCGTT ATCACTTTTT TCCTAGAAAG CATCTAACTT CATGCTTAAA ATTTGACTTT 60
ATTTGCTCAT TTAACTAGGA AAAAAAAGGT AGACCAGAAT TGCAAGGGAA TTAGCATATT 120
TCCCCAGGAA CAAAGTATTC TGAAAACAAA ACAACAGAAA ATACTGGAAA TTATGCATTT 180
TCAAGATTGA TAAGAATGCT CTTGTTTTCC CAAGCATACA TTTTTTCCCT GAAGTAGATA 240
CAGTGGAACC CATCTATATT GTAATGGGAC ATACGTTATT GTTCTGAATG CTTTAATATC 300
TAGTATTTTA GAATGTCTTT TATACTGGAT AGTAGTGTAA AATGCCTTGA GACATGCAGT 360
TGGTTTTTAG ACTTAAGACC TCTTGATGAT TGCAGACTTA CTCTTTTTTC AGTAGAGCAT 420
AGTGGAAACT AAAGAGTTTT TTAGATGAAT ATCTGGAGTA ATTTAATTAC CATTTTAATT 480
GTTCTGTATT TGCAGATAAT TGGTGATGTG AGTTTTTGAC TGACTTGAGA TTAAAATGTG 540
CTAAACCCTT ACCTGATAAC TCTCATTAGA GCAATATATG CTGGAAGCAG AGGGCTCTTG 600
TTATGGACTA AGTGTTTATG TCCCCCACAA AGTGTTGAAA TCCTAACCCC AGTGTAATGG 660
TATTAGGAGG TAGGGCCTTT GGAAAGTAAT TAGGGCATGA GGGCTCTGCC CTCATGGATG 720
GGATTCATGC TGTTATAAAA GGGACCCCAG AGAGTTCTCC TGCCCTTTTC TCACCATGTG 780
AGGATAGACA GGGAAGTCAG CTGTCTGCAA TCTGGAAGAA GGCCCTCACC AAACTCGGCT 840
GTGTTGGTAC CCTGATCTTA GATTTCCAGA TTCCAGAACT GTGAGGAATA AATGTTTGTC 900
ATTTAAGGCA CCCAGCCTGT GTAATCTGTA ATAGCAGTTC AGACTAAGAC AGCCCCATAT 960
TACTCACTCT CCATCTGAGA GTGAGCCGAG CACATAGCAT TCTTGGCATC AGTAGCACAA 1020
GGGTATGAAG GGAAATGCTT GAAGATAACT GGAATGTATA GTAGAAATGT GATTCCTGTT 1080
TATCTCTGAG TGTTAACTTT CAGAACATAG GAAATTGAGA TGCTCCCTTA AACATTCTTT 1140
TAGATAGCAA TTTAGGGAGG CAAGCTGAAC TTAAATCTTT TAGGAAATTG GACAGAGTCA 1200
TAGCCCATTG GGTTTAGAGG TAGTATAAGA AAGGTTGCTG ACATTATTTG GCTAAAGTGA 1260
ATGGAGAACA GAGTAAACCA AGAAGATAGT GTTCATGTAC ATCATCAGCA CAATACTGAG 1320
TAAGCTGAAA TATAGAAAAA TAATGTATGC TTACTATTAT TGGAATGTGA GTGACATAAG 1380
TAAATTTCAT AAAGGGAATA TAAGTCACCA CTCAAATAGT TGTTTCTTTC CTTTCCTTAA 1440
GATACAAGTG TTCCATATCT TACGGGTGAG TACAATATTG GCTGATGTGA TACGGAAAAT 1500
TCTGTCAAGT TCGGAGACAG CCATAGTGTT GAAAGTTCTG AGTGCTTTCA ACACTATCAA 1560
ATAGTGCTCA TATTCTTTCA TTGTCAGATT CCATGACCCA AGTGTGTCTG TAGGTGAAGG 1620
TCTCCCACCC CCACCCCACC CACTGATCAC TCAGTAAGCA AGCAGGCTGA TGTCTCAGTG 1680
CCTACAGTGA GCAGTGTTAA CTGACTCCTG TACTTGCTTG TCTGAGGACA GACAGGTGTG 1740
CTAGATAATT AACATTTTTT GGAAACAAAA TTATTACATT ATCCTAAAAA TAAATCAACA 1800
TACTGGGAAC ACATGCAGGA CTTTTGTATT ACTACGCAAG AAAAGATAAG CCTACTATAT 1860
TCATATAATA TATTATGAAG TCTGTTAGAT GACCTTAAAT TTGTTCATTT TTCTTATTTG 1920
ACAAGAGTTT TAAATCCCTA TGTATTTACA GATTTGGCAG ACTTGGTATG TTTTCTTCAA 1980
GCTATCATAA ACAAGCAAAT GGCTCAGAAA AATTCCCAGC TAGGTAATTT TATCTCAAAT 2040
ATCTGCTTAA 2050
|
